TriangleFOR PATIENTS · SOURCE READING
Treatment of Juvenile Myelomonocytic Leukemia
Source: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 5, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Named disease sections within a broader NCI patient summary Only the named source sections and descendants are joined. Parent source is broader; original patient terminology and grade/setting constraints must remain visible.
For information about the treatments listed below, see the Treatment Option Overview section.
Source links and citations
Treatment of newly diagnosed juvenile myelomonocytic leukemia (JMML) may include the following:
Source links and citations
Combination chemotherapy followed by stem cell transplant.
Source links and citations
Treatment of refractory or recurrent childhood JMML may include the following:
Source links and citations
A second stem cell transplant, for patients whose disease came back after the first stem cell transplant.
A clinical trial of targeted therapy with a tyrosine kinase inhibitor (trametinib).
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice